← Back to Clinical Trials
Recruiting NCT07010757

NCT07010757 Testing an Integrated PTSD and Weight Management Intervention: A Hybrid Type 1 Trial

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07010757
Status Recruiting
Phase
Sponsor VA Office of Research and Development
Condition PTSD
Study Type INTERVENTIONAL
Enrollment 182 participants
Start Date 2026-03-02
Primary Completion 2029-03-02

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
All Conditions
Interventions
HARPPcontrol arm for HARPP trial

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 182 participants in total. It began in 2026-03-02 with a primary completion date of 2029-03-02.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Obesity and post-traumatic stress disorder (PTSD) are common among Veterans. PTSD increases risk for obesity, impacting functioning, health, quality of life, and premature mortality. Use of proven treatments for PTSD and obesity in VA is low. Furthermore, Veterans with PTSD lose less weight than those without PTSD in VA's national weight management program. Based on pilot work, an integrated treatment that combines PTSD and weight management care-using behavioral and pharmacologic approaches-may improve weight and PTSD. Whether it improves these outcomes more than standard VA care is unknown, which is the focus of this study. The study also seeks to understand factors that would interfere with and facilitate implementing the program in VA if it is effective. This Veteran-centered program may be a more efficient and effective treatment for Veterans with PTSD and obesity, addressing both physical and mental health.

Eligibility Criteria

Inclusion Criteria: 1. Veteran adult 2. Current PTSD Diagnosis per the revised Clinician-Administered PTSD Scale for DSM-5 (CAPS-5-R) 3. Obesity: BMI of 30 kg/m2 4. Enrolled in VA Puget Sound primary care to ensure safety and facilitate HARPP's medication component 5. Willing to do intervention or control and assessments Exclusion Criteria: 1. Not fluent in English, severe hearing loss, no phone access 2. Recent MOVE! or CPT participation (2 visits in past 2 months) 3. Had bariatric surgery in past 6 months or plans to receive it in next 12 months 4. At least 1 fill of AOM in the past 90 days 5. Current pregnancy 6. Any history of a bulimia diagnosis and/or meets criteria for bulimia 7. Cannot participate due to a) acute substance use, mental health, or medical exacerbation or b) at least moderate neurologic conditions, e.g., dementia 8. Current weight 600lbs or greater to accommodate study scale restrictions 9. Unable to complete a standing weight and height measurement to accommodate study scale restrictions

Contact & Investigator

Central Contact

Michelle L Upham, MSW

✉ michelle.upham@va.gov

📞 (206) 277-1961

Principal Investigator

Katherine D Hoerster, PhD MPH BA

PRINCIPAL INVESTIGATOR

VA Puget Sound Health Care System Seattle Division, Seattle, WA

Frequently Asked Questions

Who can join the NCT07010757 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying PTSD. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07010757 currently recruiting?

Yes, NCT07010757 is actively recruiting participants. Contact the research team at michelle.upham@va.gov for enrollment information.

Where is the NCT07010757 trial being conducted?

This trial is being conducted at Seattle, United States.

Who is sponsoring the NCT07010757 clinical trial?

NCT07010757 is sponsored by VA Office of Research and Development. The principal investigator is Katherine D Hoerster, PhD MPH BA at VA Puget Sound Health Care System Seattle Division, Seattle, WA. The trial plans to enroll 182 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology